Moleculin secures Australian patent for Annamycin formulation technology
MBRX•Moleculin Biotech secured an Australian patent covering preparation of preliposomal Annamycin lyophilizate. The patent was granted jointly to the company and The Board of Regents of The University of Texas System.
1. Patent granted
Moleculin Biotech secured an Australian patent covering preparation of preliposomal Annamycin lyophilizate, strengthening international protection for its formulation technology. The patent was granted jointly to the company and The Board of Regents of The University of Texas System. Annamycin is in clinical development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
